Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Gynecologic Oncology Group

Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer a gynecologic oncology group study. J Clin Oncol 2003 21 3194-3200. [Pg.1394]

Rose PG, Blessing fA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma a Gynecologic Oncology Group study. Gynecol Oncol 2003 88 130-135. [Pg.1394]

Stehman FB, Bundy BN, Keys H, et al. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. A preliminary report of a Gynecologic Oncology Group study. Am J Obstet Gynecol 1988 159 87-94. [Pg.317]

Stehman FB, Bundy BN, Thomas G, et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993 11 1523-1528. [Pg.317]

Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998 42 79-85. [Pg.319]

Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes A Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 2000 48 1007-1013. [Pg.319]

Intraperitoneal chemotherapy has been under investigation for many years and accumulating positive indicators were recently reinforced by the phase III Gynecology Oncology Group study [GOG 172] (see Armstrong et al., 2006). This study randomized optimally debulked patients to either intravenous paclitaxel and cisplatin or to intravenous paclitaxel plus intraperitoneal paclitaxel and cisplatin. After a median follow-up of four years an overall survival advantage for the IP arm of 65.6 versus 49.7 months was seen. [Pg.715]

Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium a Gynecologic Oncology Group study. Gynecol Oncol 1996 62 278-81. [Pg.724]

Fleming GF, Brunetto VL, Celia D, Look KY, Reid GC, Munkarah AR et al. Phase III study of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma a Gynecologic Oncology Group study. J Clin Oncol 2004 22 2159-66. [Pg.725]

Long HJ 3rd, Bundy BN, Grendys EC Jr, Bewda JA, McMeekin DS, Sorosky J et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix a Gynecologic Oncology Group study. J Clin Oncol 2005 23 4626-33. [Pg.725]

Thigpen JT, Blessing JA, Hatch K, Barrett M, Adelson M, DiSaia P. A randomized trial of medroxyprogesterone acetate (MPA) 200 mg versus 1000 mg daily in advanced or recurrent endometrial carcinoma a Gynecologic Oncology Group (GOG) study. Proc ASCO 1991 10 185. [Pg.726]

Covens A, Brunetto VL, Markman M, Orr JW Jr, Lentz SS, Benda J. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer a Gynecologic Oncology Group study. Gynecol Oncol 2003 89 470 1. [Pg.166]

Farley, J., Smith, L.M., Darcy, K.M., Sobel, E., O Connor, D., Henderson, B., Morrison, L.E., and Birrer, M.J. 2003. Cyclin E expression is a significant predictor of survival in advanced, sub-optimally debulked ovarian epithelial cancers A gynecologic oncology group study. Cancer Res. [Pg.153]

Malfetano JH, Blessing JA, Homesley HD. A phase n trial of gallium nitrate (NSC 15200) in nonsquamous ceU carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol 1995 18(6) 495-7. [Pg.1478]

Omura GA, Brody MF, Homesly HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinomas the Gynecologic Oncology Group experience. J Clin Oncol 1991 9 1138. [Pg.2480]

McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer A Gynecologic Oncology Group study. J Clin Oncol 1995 13 1589-1599. [Pg.2480]

Rose P, Blessing J, Mayer A, Homesley H. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group Study. J Clin Oncol 1998 16 405-410. [Pg.2482]

Feun LG, Blessing JA, Major FR, et al. A Phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma A gynecologic oncology group study. Gynecol Oncol 1998 71 410-415. [Pg.2482]

Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin A trial of the Gynecologic Oncology Group. J CUn Oncol 1994 12 701-706. [Pg.2482]

Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC (1991) Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67 2776-2785... [Pg.176]

Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy a Gynecologic Oncology Group Study. Gynecol Oncol 73 177-183... [Pg.176]

Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix a Gynecologic Oncology Group Study. J Clin Oncol 2009 27(7) 1069-74. [Pg.806]

See other pages where Gynecologic Oncology Group is mentioned: [Pg.21]    [Pg.54]    [Pg.78]    [Pg.306]    [Pg.317]    [Pg.714]    [Pg.40]    [Pg.41]    [Pg.563]    [Pg.563]    [Pg.695]    [Pg.2472]    [Pg.2479]    [Pg.2481]    [Pg.2482]    [Pg.719]    [Pg.762]    [Pg.477]    [Pg.119]    [Pg.176]    [Pg.177]    [Pg.35]    [Pg.954]    [Pg.35]   
See also in sourсe #XX -- [ Pg.306 ]



SEARCH



Gynecology

OncoLogic

Oncology

© 2024 chempedia.info